This podcast, the second of a series dedicated to Multiple Myeloma in underserved populations, addresses clinical challenges in MM, with a focus on high-risk disease and cytogenetics. Prof Weisel describes the established genetic prognostic markers in MM, and the new abnormalities that are becoming important, besides the role and impact of Minimal Residual Disease (MRD) on risk status and classification of MM patients.
Podden och tillhörande omslagsbild på den här sidan tillhör European Hematology Association. Innehållet i podden är skapat av European Hematology Association och inte av, eller tillsammans med, Poddtoppen.
